Fundamentally, the MRK stock forecast rests on its diverse portfolio and low beta value, making it attractive in uncertain macroeconomic conditions. Analysts cite consistent cash flow generation as a key driver. “After posting lackluster returns in 2023, Merck & Co., Inc. (NYSE:MRK) got off to a strong start in January by raising the long-term sales forecasts for its oncology and cardiology pipelines and reporting solid fourth-quarter results, coupled with strong financial guidance for 2024. Merck shares also finished the quarter strong after receiving U.S. Food and Drug Administration approval in late March for a new cardiology medicine with the potential to contribute significantly to sales growth over the next several years.” Specifically, weak sales of Gardasil in China, a critical market for the vaccine, have unsettled investors. Furthermore, Keytruda is nearing the end of its market exclusivity period in 2028, raising questions about future revenue. Current MRK stock forecast factors in Merck’s recent FDA approval for a key cancer treatment, fueling investor optimism. Consensus EPS estimates see 2024 growth at 8%, supporting a bullish stance as defensive healthcare stocks gain attention in volatile markets.
